- Active Not Recruiting
- Treatment
- Interventional
- Randomized
- Combination Product & Procedure
- PHASE2
- Imperial College London
- 18 Years -
Study Purpose
Local cytoreductive treatments for men with newly diagnosed metastatic prostate cancer in addition to standard of care treatment
Intervention
Combination Product : Standard of Care
Procedure : Minimally Invasive Ablative Therapy (MIAT)
Procedure : Radical Therapy (Prostatectomy or Radiotherapy)
Eligibility Requirements
Diagnosed with prostate cancer within 6 months of screening visit
Metastatic disease (Any T, Any N, M1+) of any grade, stage or Prostate Specific Antigen (PSA) level.
Fit to undergo standard of care treatment for metastatic disease and both minimally invasive therapy and prostate radiotherapy/prostatectomy.
Performance status 0-2
Histologically proven local tumour
Minimum age: 18
Patient did not undergo and/or is unable to undergo standard of care baseline imaging tests for confirmation of metastatic status (CT abdomen/pelvis AND chest Xray (or CT chest) AND radioisotope bone scan (or whole body imaging such as MRI or PET imaging as alternative to all preceding scans mentioned here) AND prostate MRI.
Prior exposure to long-term androgen deprivation therapy or hormonal therapy for the treatment of prostate cancer unless started within 6 months of screening visit.
Prior chemotherapy or local or systemic therapy for treatment of prostate cancer (apart from ADT or hormonal therapy as outlined above)
Recruiting status
Active Not Recruiting
Estimated enrollment
433
Study start date
Apr 10, 2019
Study end date
Jan 31, 2027
Last updated
Mar 22, 2025
Primary purpose
Treatment
Design
Interventional
Intervention
Combination Product & Procedure
Study phase
PHASE2
Allocation
Randomized
Sponsor:
Imperial College London
Collaborator:
Wellcome Trust
Investigator:
Hashim U Ahmed, FRCS Urol
Publications
Websites
NCT03763253
Clinic | Location | Investigator | Distance | RECRUITING STATUS | Contact |
---|